Sorrento Therapeutics, Inc. (SRNE)

Institutional and Insider Ownership 0.0% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 2.6% of Sorrento Therapeutics shares are owned by insiders. Comparatively, 10.4% of NKGen Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments

Earnings and Valuation This table compares Sorrento Therapeutics and its rivals revenue, earnings per share and valuation. Gross Revenue Net Income Price/Earnings Ratio Sorrento Therapeutics $62.84 million -$572.84 million -0.01 Sorrento Therapeutics Competitors $41.99 million -$89.56 million -5.51 Sorrento Therapeutics has higher revenue, but lower earnings than its rivals. Sorrento Therapeutics is trading at a

Valuation and Earnings This table compares Sorrento Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation. Gross Revenue Net Income Price/Earnings Ratio Sorrento Therapeutics $62.84 million -$572.84 million -0.01 Sorrento Therapeutics Competitors $41.99 million -$89.56 million -5.73 Sorrento Therapeutics has higher revenue, but lower earnings than its peers. Sorrento Therapeutics is trading

Bremen, Indiana--(Newsfile Corp. - October 24, 2024) - Digger Specialties Inc. (DSI), a leading manufacturer of outdoor living products, is pleased to announce the addition of a 3-5/8" mesh infill option for the Westbury® Sorrento Mesh Railing effective November 1, 2024. Designed to provide a sophisticated, contemporary style that enhances the visual appeal of decks, balconies and porches, Westbury Sorrento Mesh Railing features unmatched long term durability and resistance to the elements.

Vancouver, British Columbia--(Newsfile Corp. - September 3, 2024) - SORRENTO RESOURCES LTD. (CSE: SRS) (OTCQB: SRSLF) (the "Company") is pleased to announce that Mr.

Vancouver, British Columbia--(Newsfile Corp. - May 29, 2024) - SORRENTO RESOURCES LTD. (CSE: SRS) (OCTQB: SRSLF) (the "Company") is pleased to announce that it has entered into a purchase agreement dated May 29, 2024 (the "Agreement") with Gold Hunter Resources Inc. (CSE: HUNT) ("Gold Hunter") for the sale of certain mineral claims around Gold Hunter's newly optioned MT property.

Vancouver, British Columbia--(Newsfile Corp. - May 8, 2024) - SORRENTO RESOURCES LTD. (CSE: SRS) (OCTQB: SRSLF) (the "Company") is pleased to announce that Mr.

Bremen, Indiana--(Newsfile Corp. - May 1, 2024) - Digger Specialties Inc. (DSI), a leading manufacturer of outdoor living products, is pleased to announce the introduction of Westbury® Sorrento Mesh Railing. Designed to provide a sophisticated, contemporary style that enhances the visual appeal of decks, balconies and porches, Westbury Sorrento Mesh Railing features unmatched long term durability and resistance to the elements.

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.

SAN DIEGO , Aug. 8, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento" or "the Debtor"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that, in connection with its ongoing chapter 11 case, the U.S. Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court") entered an order approving a $105 million "stalking horse" bid for substantially all of the Debtors' common stock, preferred stock, and warrants (in each case) in Scilex Holding Company ("Scilex" and the "Scilex Stock") to Oramed Pharmaceuticals, Inc. ("Oramed"). The stalking horse agreement with Oramed is subject to an auction and the submission of higher or otherwise better offers.

Scilex is majority owned by Sorrento, a company I will not invest in. Scilex is a more regular company, doing R&D work, selling drugs and so on. However, it is still entangled with Sorrento, and its stock price movement is too erratic for me.

Vancouver, British Columbia--(Newsfile Corp. - June 14, 2023) - Gold Hunter Resources Inc. (CSE: HUNT) ("Gold Hunter" or the "Company") is pleased to announce, further to its press release on June 6, 2023, the completion of the sale to Sorrento Resources Ltd. ("Sorrento") of a 100% interest in a portion of its claims comprising the PEG Lithium property, Harmsworth and Tom Joe properties, as well as three properties along the Doucers Valley Fault, all located in the Province of Newfoundland and Labrador (the "Property").

Vancouver, British Columbia--(Newsfile Corp. - June 6, 2023) - Gold Hunter Resources Inc. (CSE: HUNT) ("Gold Hunter" or the "Company") is pleased to announce it has entered into a mineral property purchase agreement dated June 5, 2023, pursuant to which the Company will sell to Sorrento Resources Ltd. (CSE: SRS) ("Sorrento") a 100% interest in a portion of its claims comprising the PEG Lithium property, Harmsworth and Tom Joe properties, as well as three properties along the Doucers Valley Fault, all located in the Province of Newfoundland and Labrador (the "Property").

CHICAGO, June 05, 2023 (GLOBE NEWSWIRE) -- Shanghai Escugen Biotechnology Co., Ltd. (“Escugen”), a partner of Levena (Suzhou) Biopharma Co., Ltd. (“Levena”), a wholly owned subsidiary of Sorrento Therapeutics, Inc. (Sorrento), today released preliminary results from a first-in-human study of ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients with locally advanced/metastatic solid tumors at the 2023 Annual Meeting of ASCO, the American Society of Clinical Oncology, held June 2-6 in Chicago, IL. ESG401 is an innovative ADC developed by Escugen and Levena. Escugen and Levena Biopharma jointly own the domestic and international patents of this ADC and share global rights for the product. ESG401 is composed of a humanized anti-Trop2 IgG1 monoclonal antibody (mAb) conjugated to a topoisomerase I inhibitor SN38 via a proprietary stable covalent linker with a drug antibody ratio (DAR) of 8. ESG401 has potential differentiated advantages over its competitors in terms of safety, effectiveness and process robustness. Using an innovative, highly stable and cleavable linker, this ADC demonstrated that it releases very little free toxin during circulation, which may reduce off target toxicity in a series of preclinical studies. Additionally, premature release of the mAb may compete for binding sites with the ADC to reduce its efficacy. The ADC highly enriches in tumor tissues and rapidly endocytoses, thereby effectively killing tumor cells and inhibiting tumor growth.

Any euphoria after the biotech stock's big jump yesterday didn't last long.

Sorrento Therapeutics (NASDAQ: SRNE ) stock is trending on social media today, with SRNE stock up 8% at one point this morning. This climb came after shares soared roughly 25% yesterday, although SRNE is now in the red.